Causes of sirolimus discontinuation in 97 liver transplant recipients

Transplantation Proceedings

Volumn 43, Issue 4, 2011, Pages 1128-1131

  Panaro, F ^a   Piardi, T ^a   Gheza, F ^a   Ellero, B ^a   Audet, M ^a   Cag, M ^a   Cinqualbre, J ^a   Wolf, P ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; RAPAMYCIN;

ADULT; AGED; BLOOD DISEASE; CHOLESTASIS; CHRONIC GRAFT REJECTION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOLYSIS; DIABETES MELLITUS; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; EPISTAXIS; ERYTHROPENIA; FEMALE; FOLLOW UP; FULMINANT HEPATIC FAILURE; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NAUSEA; OVERALL SURVIVAL; PANCYTOPENIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN ULCER; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT INDICATION; WOUND HEALING IMPAIRMENT;

ADOLESCENT; ADULT; AGED; CALCINEURIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ITALY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79957598915     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.01.143     Document Type: Conference Paper

References (12)

1. Campsen J, Zimmerman MA, Trotter JF, et al: Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma. Expert Opin Pharmacother 8:1275, 2007
2. Flechner SM, Kobashigawa J, Klintmalm G: Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 22:1, 2008
3. Snell GI, Westall GP: Immunosuppression for lung transplantation: evidence to date. Drugs 67:1531, 2007
4. Pallet N, Thervet E, Legendre C, et al: Sirolimus early graft nephrotoxicity: clinical and experimental data. Curr Drug Saf 1:179, 2006
5. Leogrande D, Teutonico A, Ranieri E, et al: Monitoring biological action of rapamycin in renal transplantation. Am J Kidney Dis 50:314, 2007
6. Foster R, Zimmerman M, Trotter JF: Expanding donor options: marginal, living, and split donors. Clin Liver Dis 11:417, 2007
7. Sanchez EQ, Martin AP, Ikegami T, et al: Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years. Transplant Proc 37:4416, 2005
8. Nocera A, Andorno E, Tagliamacco A, et al: Sirolimus therapy in liver transplant patients: an initial experience at a single center. Transplant Proc 40:1950, 2008
9. Schumacher G, Oidtmann M, Rueggeberg A, et al: Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 11:1420, 2005
10. Zaghla H, Selby RR, Chan LS, et al: A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation. Aliment Pharmacol Ther 23:513, 2006
11. Kasiske BL, de Mattos A, Flechner SM, et al: Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 8:1384, 2008
12. Vivarelli M, Dazzi A, Cucchetti A, et al: Sirolimus in liver transplant recipients: a large single- center experience. Transplant Proc 42:2579, 2010